Amycretin - Novo Nordisk
Alternative Names: NN-9847; NN9490 – Sc Amycretin; NNC-04870111Latest Information Update: 13 Jan 2025
Price :
$50 *
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Obesity therapies; Peptide hormones
- Mechanism of Action Amylin receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- Phase I Obesity
Most Recent Events
- 27 Nov 2024 Novo Nordisk completes a phase I trial in Obesity in USA (SC) (NCT06064006)
- 09 Sep 2024 Efficacy and adverse event data from a phase I trial in Obesity at the 60th Annual Meeting of the European Association for the Study of Diabetes 2024 (EASD-2024)
- 20 Aug 2024 Novo Nordisk plans a phase I pharmacokinetics trial in Germany (SC) (NCT06559527)